The immunopathology of sepsis and potential therapeutic targets

被引:1302
|
作者
van der Poll, Tom [1 ,2 ]
van de Veerdonk, Frank L. [3 ,4 ]
Scicluna, Brendon P. [1 ,5 ]
Netea, Mihai G. [3 ,4 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Div Infect Dis, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[3] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Geert Grooteplein Zuid 8, NL-6525 GA Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Ctr Infect Dis, Med Ctr, Geert Grooteplein Zuid 8, NL-6525 GA Nijmegen, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
基金
欧洲研究理事会;
关键词
ADAPTIVE IMMUNE DYSFUNCTION; POLYMYXIN-B HEMOPERFUSION; INTENSIVE-CARE-UNIT; SEPTIC SHOCK; CYTOKINE PRODUCTION; THYMOSIN ALPHA-1; HOST RESPONSE; RISK STRATIFICATION; ACQUIRED PNEUMONIA; INTERFERON-GAMMA;
D O I
10.1038/nri.2017.36
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. In sepsis, the immune response that is initiated by an invading pathogen fails to return to homeostasis, thus culminating in a pathological syndrome that is characterized by sustained excessive inflammation and immune suppression. Our understanding of the key mechanisms involved in the pathogenesis of sepsis has increased tremendously, yet this still needs to be translated into novel targeted therapeutic strategies. Pivotal for the clinical development of new sepsis therapies is the selection of patients on the basis of biomarkers and/or functional defects that provide specific insights into the expression or activity of the therapeutic target.
引用
收藏
页码:407 / 420
页数:14
相关论文
共 50 条
  • [1] The immunopathology of sepsis and potential therapeutic targets
    Tom van der Poll
    Frank L. van de Veerdonk
    Brendon P. Scicluna
    Mihai G. Netea
    Nature Reviews Immunology, 2017, 17 : 407 - 420
  • [2] The Pathogenesis of Sepsis and Potential Therapeutic Targets
    Huang, Min
    Cai, Shaoli
    Su, Jingqian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (21)
  • [3] The pathogenesis and potential therapeutic targets in sepsis
    Zhang, Wendan
    Jiang, Honghong
    Wu, Gaosong
    Huang, Pengli
    Wang, Haonan
    An, Huazhasng
    Liu, Sanhong
    Zhang, Weidong
    MEDCOMM, 2023, 4 (06):
  • [4] Potential therapeutic targets for sepsis in women
    Weniger, Maximilian
    D'Haese, Jan G.
    Angele, Martin K.
    Chaudry, Irshad H.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (11) : 1531 - 1543
  • [5] THERAPEUTIC TARGETS FOR SEPSIS
    Sorbera, L.
    Dulsat, C.
    Rosa, E.
    DRUGS OF THE FUTURE, 2009, 34 (09) : 765 - 770
  • [6] The Role and Mechanism of Pyroptosis and Potential Therapeutic Targets in Sepsis: A Review
    Zheng, Xiangtao
    Chen, Weiwei
    Gong, Fangchen
    Chen, Ying
    Chen, Erzhen
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [7] Circulating Histones in Sepsis: Potential Outcome Predictors and Therapeutic Targets
    Li, Yupei
    Wan, Dingyuan
    Luo, Xinyao
    Song, Tao
    Wang, Yiran
    Yu, Qiao
    Jiang, Luojia
    Liao, Ruoxi
    Zhao, Weifeng
    Su, Baihai
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [8] Apoptosis in sepsis: Mechanisms, clinical impact and potential therapeutic targets
    Ayala, Alfred
    Perl, Mario
    Venet, Fabienne
    Lomas-Neira, Joanne
    Swan, Ryan
    Chung, Chun-Shiang
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (19) : 1853 - 1859
  • [9] Emerging therapeutic targets for sepsis
    Tindal, Elizabeth W.
    Armstead, Brandon E.
    Monaghan, Sean F.
    Heffernan, Daithi S.
    Ayala, Alfred
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (03) : 175 - 189
  • [10] ECTONUCLEOTIDASES AS THERAPEUTIC TARGETS IN SEPSIS
    Hasko, G.
    SHOCK, 2016, 45 (06): : 35 - 35